Summary
The disposition of total and ultrafilterable cisplatin was determined in 12 women with ovarian carcinoma receiving cyclophosphamide 500 mg/m2, adriamycin 50 mg/m2 and cisplatin 50 mg/m2 during their first and second course. Plasma samples were obtained over 96 h following the completion of the cisplatin infusion and assayed for total platinum by atomic absorption spectroscopy. Plasma samples obtained up to 4 h after cisplatin infusion contained measurable ultrafilterable (free) cisplatin. The mean disposition of free cisplatin conformed to a two-compartment model with a mean terminal half-life (±SD) of 46.2±20.2 min during the first course and 37.8±18.0 min during the second course of therapy.
The mean disposition of total cisplatin conformed to a three-compartment model with a mean terminal half-life (±SD) of 57.8±19.3 h during the first course and 86.6±33.3 h during the second course of therapy. We found that the mean total cisplatin levels were significantly higher during the second course than the first course and the total body clearance of total platinum decreased from the first to the second course. Divided urine collections were obtained over 24 h after completion of cisplatin infusion, but cisplatin was not always detectable at all time intervals. The total fraction recovered was 0.14 and 0.12 of administered dose after the first and the second course, respectively. Renal clearance was 0.61±0.32 l/h/m2 and 0.45±0.16 l/h/m2 for the first and the second course, respectively.
We conclude that: (1) urinary platinum excretion is variable between patients and with time; (2) a trend to decreased renal clearance of platinum from first to second course may be due to a decrease in renal excretion of cisplatin; and (3) the body's elimination pathways clear less platinum upon repeat administration.
Similar content being viewed by others
References
Bannister SJ, Chang Y, Sternson LA, Repta AJ (1978) Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum (II). Clin Chem 24:877
Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123
Chang Y, Sternson LA, Repta AJ (1978) Development of a specific analytical method for cisplatin-dichlorodiammeplatinum (II) in plasma. Anal Lett B 11:449
Crom WR, Evans WE, Pratt CB, Senzer N, Denison M, Green AA, Hayes FA, Yee GC (1981) Cisplatin disposition in children and adolescents with cancer. Cancer Chemother Pharmacol 6:95
D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115
Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
Gormley PE, Bull JM, Le Roy AF, Cysyk R (1979) Kinetics of cisdichlorodiammineplatinum. Clin Pharmacol Ther 25:351
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658
Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA, Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and I.V. infusion of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 62:1359
Pera MF Jr, Harder HC (1977) Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23:1245
Prestayko AW, D'Aoust JC, Issell BF, Crooke ST (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 6:17
Remtulla MA, Soldin SJ (1982) Analysis of Cisplatin in plasma and ultrafiltrate of whole blood. Clin Chem 28:1572
Remtulla MA, Soldin SJ (1982) Studies of in vitro binding of cisplatin to plasma and whole blood. Clin Biochem 15:90
Vermorken JB, Van Der Vijgh WJF, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18:1069
Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum (II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39:365
Author information
Authors and Affiliations
Additional information
Supported in part by a grant from Adria Laboratories, Columbus, Ohio
Rights and permissions
About this article
Cite this article
Erlichman, C., Soldin, S.J., Thiessen, J.J. et al. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer. Cancer Chemother. Pharmacol. 19, 75–79 (1987). https://doi.org/10.1007/BF00296261
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00296261